Oxford, UK – 09 September 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is inviting delegates of the British Society for Genetic Medicine (BSGM) conference to join its seminar entitled “Genomic profiling of cancer – from aCGH to NGS” on Tuesday 17 September, 12.30-13.30.
Professor Bass Hassan, Professor of Medical Oncology at the University of Oxford, will be guest speaker at the seminar, where he will discuss his latest research: “Integrating NGS technology into a bench to bedside clinical programme in rare cancers”. Professor Hassan is a close collaborator with OGT, whose expertise in genomic technologies is central to his research. In a recent study working on the genomic characterisation of a number of sarcoma cell lines, he benefited from OGT’s expertise in areas including targeted sequencing (exome and cancer panels), low-depth whole genome sequencing, RNA-Seq and aCGH. As a “hot topic” in medical genetics, the seminar presents an ideal opportunity for researchers to hear more about the clinical application of NGS.
OGT’s microarray and sequencing products and services enable rapid access to meaningful, high-quality results. A range of cancer-specific options are available, including the SureSeq™ Solid Tumour Panel NGS Service and CytoSure arrays optimised for the rapid detection of CNV and LOH in haematological and solid tumours.
Delegates of BSGM conference can also visit booth 25, where they will not only have the chance to discuss how OGT can enhance their research, but can also enter into the prize draw to win an Amazon Kindle Fire Tablet.
Book online to reserve your place at the seminar. For more information on OGT’s products and services, contact OGT or visit the website.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.com
W: www.ogt.com ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Help employers find you! Check out all the jobs and post your resume.
